You can buy or sell MYGN and other stocks, options, ETFs, and crypto commission-free!
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through Diagnostics and Other segments. Read More The Diagnostics segment engages in the provision of testing and collaborative development of testing that is designed to asses a risk of developing a disease later in life of an individual. The Other segmeng provides products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and includes corporate services such as finance, human resources, legal and information technology. The company was founded by Walter A. Gilbert, Mark H. Skolnick and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake, UT.
Salt Lake City, Utah
52 Week High
52 Week Low
Advertising and Marketing
Research And Development
Markets InsiderMar 21
Myriad to Present 18 Studies at the 2019 Annual Clinical Genetics Meeting
SALT LAKE CITY, March 21, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that its Myriad Women’s Health business unit will present data from 18 studies at the 2019 Annual Clinical Genetics Meeting (ACMG) being held April 2-6, 2019 in Seattle. “We are excited to be presenting new data across multiple genetic tests at ACMG and to highlight our progress in advancing precision medicine for women,” said James Goldberg, M.D., board certified mate...
Yahoo FinanceMar 18
Myriad's myPath Melanoma Test Awarded Medicare Coverage
Myriad Genetics, Inc. MYGN recently announced the issuance of a final local coverage determination (LCD) by the Medicare Administrative Contractor Palmetto GBA MolDx for the myPath Melanoma test. Notably, myPath Melanoma is a clinically confirmed test to be used as an adjunct to histopathology. The test holds importance when histopathology alone cannot conclusively differentiate between a benign nevus and a malignant melanoma. Moreover, the myPath Melanoma test examines 23 genes and has demonstrated accura...
The Motley FoolMar 11
Here's Why Genetic Testing Stocks Rose as Much as 42.9% in February
What happened February was a great month for genetic testing stocks. Shares of Invitae (NYSE:NVTA) paced the pack with a monthly gain of 42.9%, according to data provided by S&P Global Market Intelligence. That was followed by NeoGenomics (NASDAQ:NEO) and Myriad Genetics (NASDAQ:MYGN), which rose 17.9% and 10.1%, respectively. Each stock soared on the heels of impressive quarterly operating results. The industry has long been a source of eye-popping growth, but is now harboring multiple profitable busines...
Expected May 7, After Hours